Producción científica por año
Producción científica por año
Huella digital
Profundizar en los temas de investigación en los que Carlayne E Jackson está activo. Estas etiquetas de temas provienen de las obras de esta persona. Juntos, forma una huella digital única.
- 1 Perfiles similares
Colaboraciones y áreas de investigación principales de los últimos cinco años
Colaboración externa reciente a nivel de país/territorio. Para consultar los detalles, haga clic en los puntos o
-
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success
Shefner, J. M., Al-Chalabi, A., Andrews, J. A., Chio, A., De Carvalho, M., Cockroft, B. M., Corcia, P., Couratier, P., Cudkowicz, M. E., Genge, A., Hardiman, O., Heiman-Patterson, T., Henderson, R. D., Ingre, C., Jackson, C. E., Johnston, W., Lechtzin, N., Ludolph, A., Maragakis, N. J., Miller, T. M., y 12 otros, 2023, En: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24, 5-6, p. 523-534 12 p.Producción científica: Article › revisión exhaustiva
Acceso abierto -
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS
Gebrehiwet, P., Meng, L., Rudnicki, S. A., Sarocco, P., Wei, J., Wolff, A. A., Butzner, M., Chiò, A., Andrews, J. A., Genge, A., Hughes, D. A., Jackson, C. E., Lechtzin, N., Miller, T. M. & Shefner, J. M., 2023, En: Journal of Medical Economics. 26, 1, p. 488-493 6 p.Producción científica: Article › revisión exhaustiva
Acceso abierto -
MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial
Gebrehiwet, P., Meng, L., Rudnicki, S. A., Sarocco, P., Wei, J., Wolff, A. A., Chiò, A., Andrews, J. A., Genge, A., Jackson, C. E., Lechtzin, N., Miller, T. M. & Shefner, J. M., 2023, En: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24, 3-4, p. 304-310 7 p.Producción científica: Article › revisión exhaustiva
Acceso abierto1 Cita (Scopus) -
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
Genge, A., Pattee, G. L., Sobue, G., Aoki, M., Yoshino, H., Couratier, P., Lunetta, C., Petri, S., Selness, D., Bidani, S., Hirai, M., Sakata, T., Salah, A., Apple, S., Wamil, A., Kalin, A. & Jackson, C. E., feb 2023, En: Muscle and Nerve. 67, 2, p. 124-129 6 p.Producción científica: Article › revisión exhaustiva
Acceso abierto4 Citas (Scopus) -
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
for the Healey ALS Platform Trial Study Group, HEALEY ALS Platform Trial Study Group, Biostatisticians, Investigators, Clinical Operations Team & Medical Monitors, feb 1 2022, En: Annals of neurology. 91, 2, p. 165-175 11 p.Producción científica: Article › revisión exhaustiva
Acceso abierto27 Citas (Scopus)
Conjuntos de datos
-
Data from: Validation of serum neurofilaments as prognostic & potential pharmacodynamic biomarkers for ALS
Benatar, M. (Contributor), Zhang, L. (Contributor), Wang, L. (Contributor), Granit, V. (Contributor), Statland, J. (Contributor), Barohn, R. (Contributor), Swenson, A. (Contributor), Ravits, J. (Contributor), Jackson, C. E. (Contributor), Burns, T. M. (Contributor), Trivedi, J. (Contributor), Pioro, E. P. (Contributor), Caress, J. (Contributor), Katz, J. (Contributor), McCauley, J. L. (Contributor), Rademakers, R. (Contributor), Malaspina, A. (Contributor), Ostrow, L. W. (Contributor), Wuu, J. (Contributor), Ravitz, J. (Contributor) & Wuu, J. (Contributor), ZENODO, may 27 2020
DOI: 10.5061/dryad.ttdz08ktb, https://zenodo.org/record/3859988
Dataset
-
Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset
Kim, H. S. (Creator), Son, J. (Creator), Lee, D. (Creator), Tsai, J. (Creator), Wang, D. (Creator), Chocron, E. S. (Creator), Jeong, S. (Creator), Kittrell, P. (Creator), Murchison, C. F. (Creator), Kennedy, R. E. (Creator), Tobon, A. (Creator), Jackson, C. E. (Creator) & Pickering, A. M. (Creator), Figshare, 2022
DOI: 10.6084/m9.figshare.c.5853436.v1, https://springernature.figshare.com/collections/Gut-_and_oral-dysbiosis_differentially_impact_spinal-_and_bulbar-onset_ALS_predicting_ALS_severity_and_potentially_determining_the_location_of_disease_onset/5853436/1
Dataset
-
Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset
Kim, H. S. (Creator), Son, J. (Creator), Lee, D. (Creator), Tsai, J. (Creator), Wang, D. (Creator), Chocron, E. S. (Creator), Jeong, S. (Creator), Kittrell, P. (Creator), Murchison, C. F. (Creator), Kennedy, R. E. (Creator), Tobon, A. (Creator), Jackson, C. E. (Creator) & Pickering, A. M. (Creator), Figshare, 2022
DOI: 10.6084/m9.figshare.c.5853436, https://springernature.figshare.com/collections/Gut-_and_oral-dysbiosis_differentially_impact_spinal-_and_bulbar-onset_ALS_predicting_ALS_severity_and_potentially_determining_the_location_of_disease_onset/5853436
Dataset